Skip to main content

Cancer Immunology, Immunotherapy

Ausgabe 6/2020

Inhalt (21 Artikel)

Review

Advances and perspectives of dendritic cell-based active immunotherapies in follicular lymphoma

Maria Christina Cox, Caterina Lapenta, Stefano M. Santini

Original Article

Development and characterization of a novel anti-OX40 antibody for potent immune activation

Zhihui Kuang, Hua Jing, Zhihai Wu, Jie Wang, Yiming Li, Haiqing Ni, Pan Zhang, Weiwei Wu, Min Wu, Shuaixiang Zhou, Xuan Qiu, Dongdong Wu, Bianka Prinz, Hemanta Baruah, Bingliang Chen, Michael Yu, Junjian Liu

Original Article

miRNA-5119 regulates immune checkpoints in dendritic cells to enhance breast cancer immunotherapy

Meng Zhang, Yanmei Shi, Yujuan Zhang, Yifan Wang, Faizah Alotaibi, Li Qiu, Hongmei Wang, Shanshan Peng, Yanling Liu, Qing Li, Dian Gao, Zhigang Wang, Keng Yuan, Fang-fang Dou, James Koropatnick, Jianping Xiong, Weiping Min

Original Article

CD1d expression and invariant natural killer T-cell numbers are reduced in patients with upper gastrointestinal cancers and are further impaired by commonly used chemotherapies

Ashanty M. Melo, Melissa J. Conroy, Emma K. Foley, Éilis Dockry, Eamon P. Breen, John V. Reynolds, Joanne Lysaght, Derek G. Doherty

Original Article

Nivolumab in patients with metastatic renal cell carcinoma and chronic hepatitis C virus infection

Ilya Tsimafeyeu, Rustem Gafanov, Svetlana Protsenko, Anna Semenova, Ani Oganesyan, Nurzhan Nurgaliyev, Sergei Krasny, Anastasia Bondarenko, Sufia Safina, Kristina Zakurdaeva

Original Article

Phosphorylated vimentin as an immunotherapeutic target against metastatic colorectal cancer

Mizuho Ohara, Kenzo Ohara, Takumi Kumai, Takayuki Ohkuri, Toshihiro Nagato, Yui Hirata-Nozaki, Akemi Kosaka, Marino Nagata, Ryusuke Hayashi, Shohei Harabuchi, Yuki Yajima, Kensuke Oikawa, Yasuaki Harabuchi, Yasuo Sumi, Hiroyuki Furukawa, Hiroya Kobayashi

Original Article

Critical role of PD-L1 expression on non-tumor cells rather than on tumor cells for effective anti-PD-L1 immunotherapy in a transplantable mouse hematopoietic tumor model

Jose-Ignacio Rodriguez-Barbosa, Miyuki Azuma, Gennadiy Zelinskyy, Jose-Antonio Perez-Simon, Maria-Luisa del Rio

Open Access Original Article

Oncolytic Newcastle disease virus activation of the innate immune response and priming of antitumor adaptive responses in vitro

Shannon Burke, Amy Shergold, Matthew J. Elder, Justine Whitworth, Xing Cheng, Hong Jin, Robert W. Wilkinson, James Harper, Danielle K. Carroll

Open Access Original Article

Prostaglandin E2 in a TLR3- and 7/8-agonist-based DC maturation cocktail generates mature, cytokine-producing, migratory DCs but impairs antigen cross-presentation to CD8+ T cells

Philipp Gierlich, Veronika Lex, Antje Technau, Anne Keupp, Lorenz Morper, Amelie Glunz, Hanno Sennholz, Johannes Rachor, Sascha Sauer, Ana Marcu, Götz Ulrich Grigoleit, Matthias Wölfl, Paul G. Schlegel, Matthias Eyrich

Open Access Original Article

Anti-inflammatory microenvironment of esophageal adenocarcinomas negatively impacts survival

Karl-Frederick Karstens, Jan Kempski, Anastasios D. Giannou, Penelope Pelczar, Babett Steglich, Stefan Steurer, Eric Freiwald, Anna Woestemeier, Leonie Konczalla, Michael Tachezy, Matthias Reeh, Maximilian Bockhorn, Daniel Perez, Oliver Mann, Ansgar W. Lohse, Thomas Roesch, Jakob R. Izbicki, Nicola Gagliani, Samuel Huber

Original Article

Identification and validation of tumour microenvironment-based immune molecular subgroups for gastric cancer: immunotherapeutic implications

Yu-Jie Zhou, Gui-Qi Zhu, Xiao-Fan Lu, Kenneth I. Zheng, Qi-Wen Wang, Jin-Nan Chen, Qing-Wei Zhang, Fang-Rong Yan, Xiao-Bo Li

Original Article

Myeloid-derived suppressor cells impede T cell functionality and promote Th17 differentiation in oral squamous cell carcinoma

Asif A. Dar, Rushikesh S. Patil, Trupti N. Pradhan, Devendra A. Chaukar, Anil K. D’Cruz, Shubhada V. Chiplunkar

Original Article

Clinical relevance of the comparative expression of immune checkpoint markers with the clinicopathological findings in patients with primary and chemoreduced retinoblastoma

Lata Singh, Mithalesh Kumar Singh, Moshahid Alam Rizvi, Sameer Bakhshi, Rachna Meel, Neiwete Lomi, Seema Sen, Seema Kashyap

Open Access Original Article

Inhibition of IDO leads to IL-6-dependent systemic inflammation in mice when combined with photodynamic therapy

Malgorzata Wachowska, Joanna Stachura, Katarzyna Tonecka, Klaudyna Fidyt, Agata Braniewska, Zuzanna Sas, Iwona Kotula, Tomasz Piotr Rygiel, Louis Boon, Jakub Golab, Angelika Muchowicz

Open Access Original Article

Neutrophils are mediators of metastatic prostate cancer progression in bone

Diane L. Costanzo-Garvey, Tyler Keeley, Adam J. Case, Gabrielle F. Watson, Massar Alsamraae, Yangsheng Yu, Kaihong Su, Cortney E. Heim, Tammy Kielian, Colm Morrissey, Jeremy S. Frieling, Leah M. Cook

Clinical Trial Report

Intratumoral injection of hemagglutinating virus of Japan-envelope vector yielded an antitumor effect for advanced melanoma: a phase I/IIa clinical study

Eiji Kiyohara, Atsushi Tanemura, Megumi Nishioka, Mizuho Yamada, Aya Tanaka, Akinori Yokomi, Atsuhiro Saito, Kazuma Sakura, Toshihiro Nakajima, Akira Myoui, Toshiharu Sakurai, Yutaka Kawakami, Yasufumi Kaneda, Ichiro Katayama

Meeting Report

Cancer bio-immunotherapy XVI annual NIBIT-(Italian Network for Tumor Biotherapy) meeting, October 11–13 2018, Milan, Italy

Matteo Bellone, Arianna Brevi, Stefania Bruzzì, Michela Consonni, Francesca De Santis, Giulia Di Lullo, Maria Teresa Majorini, Anna Pastò, Alberto Amadori, Marco Bregni, Massimo Di Nicola, Luana Calabrò, Pier Francesco Ferrucci, Enrico Proietti, Mario Paolo Colombo, Vincenzo Russo

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.